Li-Tzy Wu, DSc

Professor in Psychiatry and Behavioral Sciences
Professor in Medicine
Faculty Network Member of the Duke Institute for Brain Sciences
Affiliate of the Center for Child and Family Policy
Campus mail Duke Psychiatry, DUMC Box # 11, Durham, NC 27710
Phone (919) 889-9369
Email address

Education/Training: Pre- and post-doctoral training in mental health service research, psychiatric epidemiology (NIMH T32), and addiction epidemiology (NIDA T32) from Johns Hopkins University School of Public Health (Maryland); Fellow of the NIH Summer Institute on the Design and Conduct of Randomized Clinical Trials.

Director: Duke Community Based Substance Use Disorder Research Program.
Research interests: COVID-19, Opioid misuse, Opioid overdose, Opioid use disorder, Opioid addiction prevention and treatment, Pain and addiction, Chronic diseases and substance use disorders, diabetes, pharmacy-based care models and services, medication treatment for opioid use disorder (MOUD), Drug overdose, Polysubstance use and disorders, cannabis, alcohol, tobacco, hallucinogens, stimulants, e-cigarette, SBIRT (substance use Screening, Brief Intervention, Referral to Treatment), EHR-based research and intervention, data science, psychometric analysis (IRT), epidemiology of addictions and comorbidity, behavioral health care integration, health services research (mental health disorders, substance use disorders, chronic diseases), nosology, research design, HIV risk behavior. 

FUNDED Research projects (Principal Investigator [PI], Site PI, or Sub-award PI): 
R03: Substance use/dependence (PI).
R21: Treatment use for alcohol use disorders (PI).
R21: Inhalant use & disorders (PI).
R01: MDMA/hallucinogen use/disorders (PI).
R01: Prescription pain reliever (opioids) misuse and use disorders (PI).
R01: Substance use disorders in adolescents (PI).
R21: CTN Substance use diagnoses & treatment (PI).
R33: CTN Substance use diagnoses & treatment (PI).
R01: Evolution of Psychopathology in the Population (ECA Duke site PI).
R01: Substance use disorders and treatment use among Asian Americans and Pacific Islanders (PI).
UG1: SBIRT in Primary Care (NIDA, PI).
UG1: TAPS Tool, Substance use screening tool validation in primary care (NIDA, PI).
UG1: NIDA CTN Mid-Southern Node (Clinical Trials Network, PI).
UG1: EHR Data Element Study (NIDA, PI).
UG1: Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder (NIDA, PI).
PCORI: INSPIRE-Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain (Site PI).
CDC R01: Evaluation of state-mandated acute and post-surgical pain-specific CDC opioid prescribing (Site PI).
Pilot: Measuring Opioid Use Disorders in Secondary Electronic Health Records Data (Carolinas Collaborative Grant: Duke PI).
R21: Developing a prevention model of alcohol use disorder for Pacific Islander young adults (Subaward PI, Investigator).
UG1: Subthreshold Opioid Use Disorder Prevention Trial (NIH HEAL Initiative) (NIDA supplement, CTN-0101, Investigator).
NIDA: A Pilot Study to Permit Opioid Treatment Program Physicians to Prescribe Methadone through Community Pharmacies for their Stable Methadone Patients (NIDA/FRI: Study PI).
UG1: Integrating pharmacy-based prevention and treatment of opioid and other substance use disorders: A survey of pharmacists and stakeholder (NIH HEAL Initiative, NIDA, PI).
UG1: NorthStar Node of the Clinical Trials Network (NIDA, Site PI).
R34: Intervention Development and Pilot Study to Reduce Untreated Native Hawaiian and Pacific Islander Opioid Use Disorders (Subaward PI, Investigator).
UG1: Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL Study) (NIDA, Site PI).

Education and Training

  • D.Sc., Johns Hopkins University, 1997
  • M.A., State University of New York, New Paltz, 1992


Wu, Li-Tzy, Udi E. Ghitza, He Zhu, Susan Spratt, Marvin Swartz, and Paolo Mannelli. “Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes.” Drug Alcohol Depend 186 (May 1, 2018): 86–93.

Full Text

Park, Ji-Yeun, and Li-Tzy Wu. “Differences in behavioral health disorders and unmet treatment needs between medical marijuana users and recreational marijuana users: Results from a national adult sample.” Drug Alcohol Depend 180 (November 1, 2017): 311–18.

Full Text

Wu, Li-Tzy, Jennifer McNeely, Geetha A. Subramaniam, Kathleen T. Brady, Gaurav Sharma, Paul VanVeldhuisen, He Zhu, and Robert P. Schwartz. “DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.” Drug Alcohol Depend 179 (October 1, 2017): 42–46.

Full Text

Gryczynski, Jan, Jennifer McNeely, Li-Tzy Wu, Geetha A. Subramaniam, Dace S. Svikis, Lauretta A. Cathers, Gaurav Sharma, et al. “Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care.” J Gen Intern Med 32, no. 9 (September 2017): 990–96.

Full Text

Wu, Li-Tzy, He Zhu, Paolo Mannelli, and Marvin S. Swartz. “Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.” Drug Alcohol Depend 177 (August 1, 2017): 153–62.

Full Text

Hu, Hui, William W. Eaton, James C. Anthony, Li-Tzy Wu, and Linda B. Cottler. “Age of first drunkenness and risks for all-cause mortality: A 27-year follow-up from the epidemiologic catchment area study.” Drug Alcohol Depend 176 (July 1, 2017): 148–53.

Full Text

Schwartz, R. P., J. McNeely, L. T. Wu, G. Sharma, A. Wahle, C. Cushing, C. D. Nordeck, et al. “Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST.” J Subst Abuse Treat 76 (May 2017): 69–76.

Full Text